High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis

Table 2

Results of subgroup analyses for prognostic significance of platelet to lymphocyte ratio.

	Disease-free survival	Overall survival
Overall	HR = 1.47 [1.16–1.85], Tau^2 = 0.070, %	HR = 1.88 [1.27–2.80], Tau^2 = 0.192, %
	Without Allan: HR = 1.30 [1.14–1.48], Tau^2 = 0.046, %	Without Cihan: HR = 1.89 [1.52–2.34], Tau^2 = 0.099, %
Sampling time
Preoperative	HR = 1.66 [1.21–2.27], Tau^2 = 0.126, %	HR = 1.71 [1.14–2.57], Tau^2 = 0.155, %
	Without Allan: HR = 1.53 [1.13–2.06], Tau^2 = 0.090, %	Without Cihan: HR = 1.67 [1.30–2.13], Tau^2 = 0.062, %
Sample size
≥400	HR = 1.26 [1.07, 1.48], Tau^2 = 0.001, %	HR = 2.53 [1.79, 3.57], , %
<400	HR = 1.61 [1.14–2.28], Tau^2 = 0.142, %	HR = 1.60 [0.93–2.75], , %
	Without Allan: HR = 1.47 [1.06–2.03], Tau^2 = 0.099, %	Without Allan: HR = 1.32 [0.80–2.16], Tau^2 = 0.130, %
Metastatic status
M0	HR = 1.86 [1.18–2.92], Tau^2 = 0.192, %	HR = 1.62 [1.25–2.08], Tau^2 = 0.079, %
	Without Allan: HR = 1.63 [1.06–2.50], Tau^2 = 0.129, %	/
Cut-off point
≥180	HR = 1.99 [1.20–3.31], Tau^2 = 0.180, %	HR = 2.68 [1.89–3.78], Tau^2 < 0.001, %
	Without Allan: HR = 1.68 [1.07, 2.64], Tau^2 = 0.103, %
<180	HR = 1.27 [1.04–1.56], Tau^2 = 0.073, %	HR = 1.46 [0.92–2.31], Tau^2 = 0.135, %
	/	Without Cihan: HR = 1.51 [1.14–1.99], Tau^2 = 0.033, %
Receptor status
Her2+	HR = 1.29 [0.85–1.96], Tau^2 = 0.155, %	/
Her2−	HR = 1.30 [1.07–1.57], Tau^2 < 0.001, %	/
HR+	HR = 1.59 [1.18, 2.13], Tau^2 = 0.021, %	/
HR−	HR = 1.14 [0.93–1.41], Tau^2 < 0.001, %	/
TNBC	HR = 1.39 [1.04–1.86], Tau^2 < 0.001, %	/

Note. HER2: human epidermal growth factor receptor; HR: hazard ratio; HR+: positive hormone receptor; HR−: negative hormone receptor; M0: no-metastasis; TNBC: triple-negative breast cancer; “/” symbol: no results due to insufficient studies.